Alternative trading organization

Impact BioMedical Scientific Partner GRDG Sciences to be Featured in New Documentary

Retrieved on: 
Wednesday, October 19, 2022
Diamond, Quantum, Lists of record labels, Investment management, Cholera, Therapy, Science, R, DSS, OTC, Digital transformation, Solution, Freedom, Escherichia coli, Severe acute respiratory syndrome coronavirus 2, LLC, NYSE, Plastic, Alternative trading organization, Cancer, Prophase, Patent cliff, DARPA, Biomedicine, GLOBE, Leadership, Mission: Impossible, Tuberculosis, Research, NIH, Security (finance), Technology, Thompson, MRSA, COO, IPO, Emmy Awards, Sustainable energy, Biosafety, Partnership, Infection, Drug discovery, Linebacker, Epidemic Intelligence Service, Safety, Tom Denney, COVID-19, Pharmaceutical industry, Toy, Fine chemical, Management, Vaccine, Film, Biotechnology, Rhinovirus

ROCHESTER, N.Y., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Daryl Thompson, founder of GRDG Sciences LLC (“GRDG”) in Winter Haven, Florida, has spent a career working just out of the spotlight and inventing biological and medical technologies that, when fully deployed, could better the lives of people around the world.

Key Points: 
  • Early in the development process, GRDG began a working relationship with Impact Biomedical, who partnered with GRDG and provided investment capital to support its research.
  • Impact BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
  • Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades.
  • By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno -related diseases.

Impact BioMedical Develops Quantum Antihistamine

Retrieved on: 
Tuesday, July 26, 2022
World, Lists of record labels, Digital transformation, Biomedicine, Method, Security (finance), DSS, LLC, Population, Sustainable energy, Research, Solution, Income, World Health Organization, Technology, COVID, Alternative trading organization, EIS, Growth, IPO, GLOBE, Halogenation, Industry, Investment management, Patent, Degenerative disease, Epidemic Intelligence Service, Mark (given name), Quality of life, Therapy, Amazon, Prenylation, Global Research, ZS, ZS Associates, Medicine, R, Marriage, Toxicity, Thompson, Imagination, NYSE, Drug discovery, Pharmacy, Risk, Leadership, Patient, Fine chemical, Microscope, Vaccine, Pharmaceutical industry, Renewable energy, Generic drug, Biotechnology, Quantum

The Quantum Antihistamine is the latest breakthrough in GRDGs Quantum Project, and has been successful produced.

Key Points: 
  • The Quantum Antihistamine is the latest breakthrough in GRDGs Quantum Project, and has been successful produced.
  • Through the Quantum research project, Impact Biomedical and GRDG have taken the first step in creating a new way to make medicine.
  • Impact BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
  • Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades.

DSS Announces Licensing of Impact BioMedical’s Linebacker Portfolio to ProPhase Labs

Retrieved on: 
Thursday, July 21, 2022
Traffic barrier, IPO, GLOBE, Toxicity, Genomics, Investment management, Lists of record labels, CEO, Forward-looking statement, NYSE, SEC, Risk, Viral disease, Securities Act of 1933, Securities Exchange Act of 1934, Health, Digital transformation, Patent, Linebacker, PIM, Prophase, Safety, Prospectus, Cancer, LB-1, Leadership, Company, Security (finance), Nasdaq, DSS, Alternative trading organization, Neurology, LB-2, Sustainable energy, Pharmaceutical industry, Biotechnology

The compounds that ProPhase licensed have enormous potential and represent years of scientific research.

Key Points: 
  • The compounds that ProPhase licensed have enormous potential and represent years of scientific research.
  • I truly believe that the Linebacker portfolio represents a potential breakthrough in cancer research.
  • The execution of this licensing agreement represents is a significant milestone for Impact BioMedical and its robust portfolio of development opportunities, said Frank D. Heuszel, CEO of DSS.
  • Daryl Thompson and GRDG plan to work with ProPhase to continue the development of the Linebacker portfolio, as well as on other important compounds in the future.

DSS Strengthens and Expands Board with Appointment of Two Independent Directors

Retrieved on: 
Wednesday, July 13, 2022
Deloitte, SEC, Digital transformation, Security (finance), Lists of record labels, Leadership, Investment management, DSS, Sustainable energy, Securities Act of 1933, Company, IPO, Securities Exchange Act of 1934, CEO, Financial management, GLOBE, Patent, Risk, Forward-looking statement, CFO, Alternative trading organization, Board, Prospectus, NYSE, Board of directors, Biotechnology

Trained at Deloitte, Mr. Wong has extensive experience in real estate, property investment, property development, financial services, fund management, and asset management.

Key Points: 
  • Trained at Deloitte, Mr. Wong has extensive experience in real estate, property investment, property development, financial services, fund management, and asset management.
  • Adding Joanne and Frankie as directors further strengthens our already impressive board and brings additional depths of experience to our team as we continue to execute on our vision, said Frank D. Heuszel, CEO of DSS.
  • As we continue to pursue opportunities across nine targeted business lines, this wealth of diverse experience provides immeasurable value to DSS.
  • DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy.

DSS’s Impact BioMedical Receives China Patent for its Functional Fragrance Formulation Mosquito Repellant

Retrieved on: 
Tuesday, June 7, 2022
Science, Lists of record labels, Life, Human, Leadership, Death, Research, IPO, LLC, GMA, Patent, Chikungunya, Security (finance), Lymphatic filariasis, DSS, Malaria, Biomedicine, Sustainable energy, Solution, Global, Sale, China National Intellectual Property Administration, Zika fever, Investment management, National, GLOBE, Diabetes, Technology, Digital transformation, NYSE, Fever Dream, Alternative trading organization, Drug discovery, Food preservation, Agriculture, Medical device, Biotechnology

This complements the corresponding U.S. patent granted (U.S. 11,246,310)

Key Points: 
  • This complements the corresponding U.S. patent granted (U.S. 11,246,310)
    3F is an extremely effective mosquito repellant.
  • The repellant is believed to incapacitate two of the three receptors that mosquitoes use to find sources of nutrition.
  • Impact Biomedical and GRDG announced a U.S. patent (US 10,966,424) allowance for 3FDB in June 2021.
  • Impact BioMedical drives mission-oriented research, development, and commercialization of solutions for medical advances in human wellness and healthcare.

DSS, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Retrieved on: 
Friday, May 6, 2022
Digital transformation, DSS, Forward-looking statement, Sustainable energy, GLOBE, Company, NYSE, Securities Exchange Act of 1934, Securities Act of 1933, Security (finance), Prospectus, Risk, Patent, Leadership, Bloomberg, Wall Street, Alternative trading organization, Investment management, Lists of record labels, SEC, Interview, IPO, Biotechnology

Bloomberg U.S. is available in an estimated 73 million homes across the United States.

Key Points: 
  • Bloomberg U.S. is available in an estimated 73 million homes across the United States.
  • The RedChip Money Report is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years experience focused on Discovering Tomorrows Blue Chips Today.
  • The RedChip Money Report delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
  • DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy.